Prolapse of a pedunculated uterine leiomyoma through the cervix during GnRH antagonist treatment: Case report and literature review.
GnRH agonist
GnRH antagonist
heavy vaginal bleeding
hysterectomy
leiomyoma prolapse
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
10 Sep 2020
10 Sep 2020
Historique:
received:
01
05
2020
revised:
28
07
2020
accepted:
30
08
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
11
9
2020
Statut:
aheadofprint
Résumé
We here describe a case of the prolapse of pedunculated submucosal leiomyoma through the cervix during the treatment of a gonadotropin-releasing hormone (GnRH) antagonist relugolix. We also present the literature review of the cases of leiomyoma prolapse during GnRH modulators. A 55-year-old woman with atypical vaginal bleeding diagnosed submucosal uterine fibroid 6 cm in diameter, and daily oral administration of relugolix was conducted. On the 35th day of the administration, heavy vaginal bleeding suddenly occurred due to leiomyoma prolapse. Finally, she underwent abdominal hysterectomy to treat heavy bleeding. To date, six cases of leiomyoma prolapse during GnRH modulators have been reported, in which all the previous cases were treated with GnRH agonists. This is the first case report of leiomyoma prolapse during GnRH antagonist treatment. Notably, leiomyoma prolapse is a possible common adverse effect of GnRH modulators for the treatment of submucosal leiomyoma, which is caused by rapid decrease in its volume.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : JSPS
Informations de copyright
© 2020 Japan Society of Obstetrics and Gynecology.
Références
Munro MG, Critchley HO, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril. 2011; 95: 2204-2208 2208e1-3.
Ben-Baruch G, Schiff E, Menashe Y, Menczer J. Immediate and late outcome of vaginal myomectomy for prolapsed pedunculated submucous myoma. Obstet Gynecol 1988; 72: 858-861.
Archer DF, Stewart EA, Jain RI et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: Results from a phase 2a proof-of-concept study. Fertil Steril 2017; 108: 152-60e4.
Chipato T, Healy DL, Vollenhoven B, Buckler HM. Pelvic pain complicating LHRH analogue treatment of fibroids. Aust N Z J Obstet Gynaecol 1991; 31: 383-384.
Osuga Y, Enya K, Kudou K, Hoshiai H. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: A randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril 2019; 112: 922-929 e2.
Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist Relugolix compared with Leuprorelin injections for uterine Leiomyomas: A randomized controlled trial. Obstet Gynecol 2019; 133: 423-433.
Taylor HS, Giudice LC, Lessey BA et al. Treatment of endometriosis-associated pain with Elagolix, an Oral GnRH antagonist. N Engl J Med 2017; 377: 28-40.
Nkwabong E. An intramural uterine fibroid became submucosal in the puerperium - proposed probable mechanism: A case report. J Med Case Reports 2018; 12: 88.
Caglar GS, Tasci Y, Kayikcioglu F. Management of prolapsed pedunculated myomas. Int J Gynaecol Obstet 2005; 89: 146-147.
Ellenbogen A, Shulman A, Libal Y, Jaschevatzky O, Anderman S, Grunstein S. Complication of triptorelin treatment for uterine myomas. Lancet 1989; 2: 167-168.
Kriplani A, Agarwal N, Parul D, Bhatla N, Saxena AK. Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy. J Obstet Gynaecol 2002; 22: 449-451.
Wen L, Tseng JY, Wang PH. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist. Taiwan J Obstet Gynecol 2006; 45: 173-175.